A MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF SOLIFENACIN SUCCINATE SUSPENSION IN PEDIATRIC SUBJECTS FROM 5 TO LESS THAN 18 YEARS OF AGE WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO).

被引：0
|
作者：
Bosman, B. [1 ]
Tannenbaum, S. [1 ]
Winklewski, P. [1 ]
Den Adel, M. [1 ]
Newgreen, D. [1 ]
Baka-Ostrowska, M. [1 ]
机构：
[1] Pomnik Ctr Zdrowia Dziecka Warsaw, Warsaw, Poland
来源：
NEUROUROLOGY AND URODYNAMICS | 2013年 / 32卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
296
引用
收藏
页码：932 / 933
页数：2
相关论文
共 25 条
  • [1] Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age
    Cirillo, Iolanda
    Vaccaro, Nicole
    Castaneda-Ruiz, Bibiana
    Redman, Rebecca
    Cossey, Veerle
    Bradley, John S.
    Allegaert, Karel
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4742 - 4749
  • [2] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Trivedi, Ashit
    Mather, Omar
    Vega, Silvia
    Hutton, Shauna
    Hellawell, Jennifer
    Lee, Edward
    DRUGS IN R&D, 2022, 22 (02) : 141 - 146
  • [3] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Ashit Trivedi
    Omar Mather
    Silvia Vega
    Shauna Hutton
    Jennifer Hellawell
    Edward Lee
    Drugs in R&D, 2022, 22 : 141 - 146
  • [4] Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects
    Chen, Qian
    Qian, Hong-jie
    Wang, Wei
    Zhang, Meng-qi
    Lu, Dong-ying
    Lu, Chuan
    Jin, Jie-mei
    Hu, Chao-ying
    Liu, Gang-yi
    Jia, Jing-ying
    Zheng, Hong-chao
    Li, Xue-ning
    Yu, Chen
    Wang, Yi-ping
    Liu, Yun
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 (01) : 120 - 125
  • [5] An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
    Winnie Y. Sohn
    Anthony A. Portale
    Isidro B. Salusky
    Hao Zhang
    Lucy L. Yan
    Bella Ertik
    Shahnaz Shahinfar
    Edward Lee
    Bastian Dehmel
    Bradley A. Warady
    Pediatric Nephrology, 2019, 34 : 145 - 154
  • [6] Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
    Winnie Y. Sohn
    Anthony A. Portale
    Isidro B. Salusky
    Hao Zhang
    Lucy L. Yan
    Bella Ertik
    Shahnaz Shahinfar
    Edward Lee
    Bastian Dehmel
    Bradley A. Warady
    Pediatric Nephrology, 2019, 34 : 739 - 740
  • [7] Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Gareth, Thomas Marbury
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    CANCER RESEARCH, 2023, 83 (08)
  • [8] Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies
    Franco, Israel
    Hoebeke, Piet
    Bolong, David
    Davies, Leon N.
    Dahler, Ellen
    Snijder, Robert
    Stroosma, Otto
    Verheggen, Frank
    Newgreen, Donald
    Bosman, Brigitte
    Vande Walle, Johan
    JOURNAL OF PEDIATRIC UROLOGY, 2020, 16 (02) : 180.e1 - 180.e8
  • [9] An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28days to &lt;6years with chronic kidney disease receiving dialysis
    Sohn, Winnie Y.
    Portale, Anthony A.
    Salusky, Isidro B.
    Zhang, Hao
    Yan, Lucy L.
    Ertik, Bella
    Shahinfar, Shahnaz
    Lee, Edward
    Dehmel, Bastian
    Warady, Bradley A.
    PEDIATRIC NEPHROLOGY, 2019, 34 (01) : 145 - 154
  • [10] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
    Gardin, Anne
    Dodman, Angela
    Kalluri, Sampath
    Neelakantham, Srikanth
    Tan, Xuemei
    Legangneux, Eric
    Shakeri-Nejad, Kasra
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 54 - 65
123